Strong Revenue Growth
Revenue reached CHF 1.3 billion in the first half of 2025, with the second quarter contributing CHF 667.5 million, reflecting solid momentum across all businesses.
Organic Growth
Organic growth reached 10.2% in the first half and 9.3% in the second quarter.
Core EBIT Margin
Achieved a core EBIT margin of 26.6% despite strong currency headwinds.
Successful Product Launches
iEXCEL launches are off to a strong start, with positive clinician feedback, and regulatory approval for premium implant production in China.
Regional Performance
Strong performance in EMEA, North America, Asia Pacific, and Latin America, each contributing to growth with notable achievements in China and Brazil.
Digital and Manufacturing Investments
Continued investment in digital solutions and manufacturing expansions, including a new campus in Shanghai.
Net Profit Increase
Core net profit amounted to CHF 265 million, increasing by 16% at constant currency year-over-year.